Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gevensleben

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Der Pathologe|September 18, 2010
[Hereditary breast and ovarian cancers]H Gevensleben, N Serçe, R Büttner
HNO|March 26, 2010
[Tonsillar lymphangiomatous polyp]M Kühnemund, N Wernert, H Gevensleben, et al.
Leukemia|November 15, 2016
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemiaD Goltz, H Gevensleben, S Grünen, et al.
British Journal of Cancer|November 26, 2014
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studiesF Huber, M Montani, T Sulser, et al.
Der Pathologe|November 16, 2014
[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]G Kristiansen, B Delahunt, J R Srigley, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2021
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancerL C Hanker, A El-Balat, Z Drosos, et al.
European Child & Adolescent Psychiatry|January 6, 2019
Slow cortical potentials neurofeedback in children with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment in a multicenter randomized controlled trialPascal-M Aggensteiner, D Brandeis, S Millenet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Der Pathologe|September 18, 2010
[Hereditary breast and ovarian cancers]H Gevensleben, N Serçe, R Büttner
HNO|March 26, 2010
[Tonsillar lymphangiomatous polyp]M Kühnemund, N Wernert, H Gevensleben, et al.
Leukemia|November 15, 2016
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemiaD Goltz, H Gevensleben, S Grünen, et al.
British Journal of Cancer|November 26, 2014
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studiesF Huber, M Montani, T Sulser, et al.
Der Pathologe|November 16, 2014
[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]G Kristiansen, B Delahunt, J R Srigley, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2021
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancerL C Hanker, A El-Balat, Z Drosos, et al.
European Child & Adolescent Psychiatry|January 6, 2019
Slow cortical potentials neurofeedback in children with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment in a multicenter randomized controlled trialPascal-M Aggensteiner, D Brandeis, S Millenet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancerS K Sandhu, A Omlin, L Hylands, et al.
Pageof 1